Guardant Health, Inc. $GH Shares Bought by Emerald Advisers LLC

Emerald Advisers LLC lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 24.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 873,203 shares of the company’s stock after purchasing an additional 173,281 shares during the quarter. Guardant Health comprises about 1.7% of Emerald Advisers LLC’s investment portfolio, making the stock its 9th largest position. Emerald Advisers LLC owned approximately 0.70% of Guardant Health worth $54,558,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in GH. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Guardant Health by 54.4% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock worth $18,835,000 after buying an additional 106,263 shares in the last quarter. Inspire Advisors LLC purchased a new stake in shares of Guardant Health during the 3rd quarter worth approximately $736,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Guardant Health during the 3rd quarter worth approximately $1,189,000. Eastern Bank acquired a new stake in shares of Guardant Health in the 3rd quarter worth approximately $126,000. Finally, Bayforest Capital Ltd purchased a new position in Guardant Health in the 3rd quarter valued at approximately $78,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Activity at Guardant Health

In other news, CEO Amirali Talasaz sold 100,000 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $105.05, for a total transaction of $10,505,000.00. Following the transaction, the chief executive officer directly owned 168,223 shares in the company, valued at $17,671,826.15. This represents a 37.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Terilyn J. Monroe sold 55,167 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $105.97, for a total transaction of $5,846,046.99. Following the transaction, the insider directly owned 20,920 shares of the company’s stock, valued at $2,216,892.40. This trade represents a 72.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 436,552 shares of company stock worth $45,622,836. Corporate insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on GH. Canaccord Genuity Group boosted their target price on Guardant Health from $100.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Wells Fargo & Company raised their target price on shares of Guardant Health from $93.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, December 15th. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a report on Wednesday, January 7th. UBS Group increased their price target on shares of Guardant Health from $80.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, Piper Sandler raised their price objective on shares of Guardant Health from $60.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Twenty-one equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.81.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $115.75 on Thursday. The firm has a market cap of $14.59 billion, a P/E ratio of -36.06 and a beta of 1.58. Guardant Health, Inc. has a 1 year low of $34.88 and a 1 year high of $116.41. The firm’s 50 day moving average price is $104.37 and its 200 day moving average price is $76.71.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. The company’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.88) EPS. As a group, equities analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.